Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRND | Q07001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780146 | 0.85 | CCR2 (0.49) | CCR2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1779399 | 0.80 | CCR2 (0.55) | CCR2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1781857 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL1827584 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL14237216 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL1826285 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL14237163 | 0.76 | CCR2 (1.00) | CCR2 | |
| SCHEMBL3223363 | 0.76 | CCR2 (0.49) | CCR2SLC6A3SLC6A2SLC6A4 | |
| Bicarbonate SCHEMBL14238261 | 0.74 | CCR2 (0.51) | CCR2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1778747 | 0.72 | CCR2 (0.67) | CCR2SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507559-B2 | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | claimed |
| EP-2318352-B1 | CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | claimed |
| US-8507559-B2 | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2318352-B1 | CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| EP-2318352-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010009068-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | CCR2 2/4885SLC6A3 4370/4885CHRNA1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.